# US 7,745,194 B2 · Staphylococcus aureus: bacteriophage and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,194 B2
- Document ID: US7745194B2
- Status: Granted
- Kind: B2
- Application number: 12/211,347
- Filed: 2008-09-16
- Published: 2010-03-18
- Granted: 2010-06-29
- Earliest claimed: 2008-09-16
- Assignees: Intralytix, Inc.
- Inventors: Gary R. Pasternack; Alexander Sulakvelidze
- Web page: https://patentgrep.com/patent/US7745194B2

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2795/00021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Staphylococcus aureus, in particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Staphylococcus aureus in various settings.

## Claims

### Claim 1

An isolated bacteriophage SAML-4, SAML-150, or SATA-8505 said bacteriophages having been deposited under ATCC accession Nos. PTA-9474, PTA-9475, and PTA-9476, respectively, wherein said bacteriophage has lytic activity against Staphylococcus aureus strains.

### Claim 2

Isolated progeny of the bacteriophage SAML-4 SAML-150, or SATA-8505, wherein said progeny of said bacteriophage have the same phenotypic characteristics and same lytic activity against Staphylococcus aureus strains as said bacteriophage, and said strains having been deposited under ATCC accession Nos. PTA-9474, PTA-9475, and PTA-9476, respectively.

### Claim 3 (depends on 1)

A composition comprising an isolated bacteriophage of claim 1.

### Claim 4 (depends on 2)

A composition comprising an isolated bacteriophage of claim 2.

### Claim 5 (depends on 1)

The isolated bacteriophage of claim 1, wherein said Staphylococcus aureus strain is a MRSA (MDRSA) strain.

### Claim 6 (depends on 2)

The isolated progeny of claim 2, wherein said Staphylococcus aureus strain is a MRSA (MDRSA) strain.